Trump says U.S. may have coronavirus vaccine ‘far in advance’ of end of the year

President Donald Trump said Monday the U.S. may have a coronavirus vaccine available to the public ahead of the administration’s goal of the end of the year or early 2021.

“We’re balancing speed and safety and we’re on pace to have a vaccine available this year, maybe far in advance of the end of the year,” Trump said during a White House press briefing. “And we’re mass-producing the most promising candidates in advance so that we’re ready upon approval. We have our military lined up, it’s logistics, it’s all about logistics.”

He mentioned vaccine candidates from drug companies Pfizer and Moderna, which both began late-stage trials for their leading vaccine candidates last week, and have already vaccinated “several hundred people,” according to senior administration officials. Both potential vaccines use mRNA molecules, which scientists hope will provoke an immune response to fight the virus.

“These are companies that are not only well know, they are well respected,” Trump said. 

Because of the pandemic, U.S. health officials and researchers have been accelerating the development of vaccine candidates by investing in multiple stages of research even though doing so could be for naught if the vaccine ends up not being effective or safe.

Trump’s prediction of when the U.S. may have a vaccine may be optimistic. Though scientists expect to have an effective vaccine widely available by next year, there is never a guarantee. While drugmakers are racing to make millions of doses of vaccines, there’s a chance the vaccine will require two doses rather than one, potentially further limiting the number of people who can get vaccinated once it becomes available, experts say.

Officials also need to make sure states have the vials, needles and syringes needed to administer the vaccine or risk shortages.

Additionally, scientists say that questions remain about how the human body responds once it’s been infected with the virus. The answers, they say, may have important implications for vaccine development, including how quickly it can be deployed to the public.

One critical question among scientists is whether antibodies produced in response to Covid-19 offer protection against getting infected again. Scientists hope the antibodies provide some degree of protection against getting the virus, but they can’t say that definitively yet since it was discovered just seven months ago. 

Health officials say there is no returning to “normal” until there is a vaccine against the virus, which has infected more than 18 million people worldwide and killed at least 689,922, according to data compiled by Johns Hopkins University.

Dr. Anthony Fauci, the nation’s leading infectious disease expert, has repeatedly said he’s “cautiously optimistic” that scientists will discover a safe and effective vaccine by the end of the year or early 2021. However, he also has said that a vaccine likely won’t be “widely available” to the American public until “several months” into 2021.

Trump said Monday he hopes the U.S. will be able to end the pandemic “very, very quickly” once a vaccine is available. 

“We want to make people better,” he said, adding the U.S. will first send the vaccine to the areas that need it most. 

Reprinted from cnbc.com, the copyright all reserved by the original author.